Table 1.
Composition of investigated formulations.
| Formulation | Helper Lipid |
Helper Lipid (mol%) | Ionizable Lipid | Ionizable Lipid (mol%) | Cholesterol (mol%) | Stealth Moiety | Stealth Moiety (mol%) | mRNA (mol%) |
|---|---|---|---|---|---|---|---|---|
| LNP 1 | DOPE | 10 | DODMA | 40 | 48 | PEG | 2 | 8 |
| LNP 2 | DOPE | 10 | DODMA | 40 | 48 | pSar | 2 | 8 |
| LNP 3 | DOPC | 10 | DODMA | 40 | 48 | PEG | 2 | 8 |
| LNP 4 | DOPC | 10 | DODMA | 40 | 48 | pSar | 2 | 8 |
| LNP 5 | DOPE | 10 | MC3 | 40 | 48 | PEG | 2 | 8 |
| LNP 6 | DOPE | 10 | MC3 | 40 | 48 | pSar | 2 | 8 |
| LNP 7 | DOPC | 10 | MC3 | 40 | 48 | PEG | 2 | 8 |
| LNP 8 | DOPC | 10 | MC3 | 40 | 48 | pSar | 2 | 8 |
All formulations were manufactured with an N/P ratio of 5. Sample names for lipid nanoparticle (LNP) formulations will be used throughout the manuscript: 1,2-dioleyloxy-3-dimethylaminopropane (DODMA); DLin-MC3-DMA (MC3); 1,2-dioleoyl-sn-glycero-3-ethanolamine (DOPE), 2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), C16-PEG2000-Ceramide (PEG); polysarcosine BA12-50 (pSar).